Teva Pharmaceutical Industries Limited · TASE:TEVA
Teva Pharmaceutical Industries — Investor Day (October 2007)
11 slides from Teva Pharmaceutical Industries's investor day presentation, Oct 16, 2007
Slide 1: Global Generic Resources
Global Generic Resources Jacob Winter October 16, 2007 Forward-Looking Statements TODAY’S PRESENTATION CONTAINS FORWARD LOOKING STATEMENTS WHICH EXPRESS THE CURRENT BELIEFS AND EXPECTATIONS OF MANAGEMENT. SUCH STATEMENTS ARE BASED ON CURRENT EXPECTATIONS AND INVOLVE A NUMBER OF KNOWN AND UNKNOWN RIS
Slide 2: Wide Range of Technologies; In-house Production Volumes
Wide Range of Technologies Tablets, Capsules, MR Tablets, Powders for suspension Pre-filled syringes, Vials, Ampoules, Infusion Bags, Nebules (BFS), Ophthalmics Metered Dose Inhalers (MDI’s) Metered Dose Powder Inhalers (MDPI’s) Breath Actuated Inhalers (BAI’s) Liquids, Creams & Ointments, Nasal spr
Slide 3: Production Plants Rationalization; Manufacturing Sites
Production Plants Rationalization From 38 to 31 plants 2006 2007 2008 Glades, FL-US Idema, ON-Canada S. Boston, PA-US Pralex, USVI Cidra, Puerto Rico Muniz, Argentina Closed Marathon, Chile In Process 5 Global Generic Resources – Manufacturing Countries 19 Manufacturing sites 33 GR&D sites 15 Biotec
Slide 4: Global Generic Resources – Biotechnology
Global Generic Resources – Biotechnology Countries 19 Manufacturing sites 33 GR&D sites 15 Biotech facilities 3 Employees ~12,000 LITHUANIA Vilnius CHINA Tianjin ISRAEL Rehovot 7 Global Customer-back Supply Chain ● Decentralized lean Supply Chain organization with a customer focus and agile supply s
Slide 5: Evolution of Supply Network; Materials Purchasing Sources
Evolution of Supply Network Global Supply Chain Technological Technological Plant Profiling Centers Centers of of ● Specialized sites for new Expertise Expertise product launches ● Optimized locations for “commodity products” ● Develop technological ● Custom solutions for small Local Local Supply Su
Slide 6: Materials Sourcing & Purchasing; GR&D Sites
Materials Sourcing & Purchasing Benefits from our global structure ● Availability & flexibility – Vendors are happy to share opportunities as leveraged to several markets – Can better react to market opportunities by having global inventory ● Purchasing power – Combined quantity for all sites & mark
Slide 7: Generic R&D Goal: First to File – First to Market
Generic R&D Goal: First to File – First to Market Prerequisites for First and Fastest to Market ● Effective product selection process ● Effective patent landscape analysis ● Adequate product development plan Leveraging on Teva leadership position as a global provider of generic pharmaceuticals with
Slide 8: It's not just the number of files, but how you do it
It’s not just the number of files, but how you do it. Leveraging – Developing for more than one market Some Other US EU/CA Markets Batches 1 2 3 (Number required) Stability 3 6 6 Plus Zone IV (Months) Cost $ $ $ 15 Human Capital - GR&D Degree Spread No Degree Ph.D. 8% 11% Pharm D AS 2% 13% MS 20% BS
Slide 9: Technologies and Centers of Know-How; Quality System Approach
Technologies and Centers of Know-How Israel ● Solid Oral Complex Drug Delivery Irvine, US − Beads ● Injectable Complex Drug Delivery − Tablets – Long Acting ● Nasal Sprays ● Injectable Suspensions Sellersville, US Runcorn, UK ● Sterile Blow-Fill-Seal Products ● Orally Disintegrating Tablets ● Solid
Slide 10: Regulatory Authorities Inspections 2006-2007
Regulatory Authorities Inspections 2006-2007 The outcome of 103 inspections: Satisfactory compliance status Europe & Israel Latin 32 America Out of 103 inspections: 43 US FDA - 32 North EU Agencies - 25 America 28 19 Evolution of Global Quality Teva Teva Quality Quality Standard Standard Harmonizati
Slide 11: Jerusalem New OSD Plant
Jerusalem New OSD Plant Automatic Utilities Warehouse Labs & Offices Production 21 11
Teva Pharmaceutical Industries — Investor Day (October 2007) on 6ix